サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1428450

RSウイルス（RSV）治療薬の世界市場レポート 2024

Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
RSウイルス（RSV）治療薬の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

RSウイルス（RSV）治療薬の市場規模は、今後数年間で急激に成長すると予想されています。 2028年には23.4%の年間複合成長率（CAGR）で36億9,000万米ドルに成長すると予想されます。 RSウイルス（RSV）治療薬の予測期間の伸びは、生物学的療法の革新、新しい抗ウイルス薬の出現、高齢者人口への焦点、母親の予防接種戦略、世界の調査協力の増加などの要因に起因すると考えられます。予測期間の主な動向には、モノクローナル抗体の進歩、経鼻ワクチンと送達システムの開発、併用療法の探索、新しいドラッグデリバリーシステムの革新、在宅治療の選択肢の開発が含まれます。

RSV感染症の流行の急増により、RSウイルス（RSV）治療薬の市場の拡大が加速しています。 RSVは、特に新生児、幼児、高齢者、免疫系が低下している人の間で、軽度から重度の呼吸器感染症を引き起こす可能性がある一般的な呼吸器疾患です。 RSV感染症の発生が激化しているため、需要の増加に応え、RSV関連の合併症の重症度を軽減するための新しい治療法の必要性が高まっています。ランセット誌の2022年9月の出版物で証明されているように、2021年の夏には約11,255件の新たなRSV症例が報告され、2020年から21年の冬に記録された10,280件と比較して9.50%増加しました。したがって、RSV感染症の有病率の上昇は、RSウイルス（RSV）治療薬市場の成長の重要な推進力です。

疾病率の上昇は、RSウイルス（RSV）治療薬市場の成長軌道を推進する重要な要因です。病気とは、感染、遺伝子異常、環境ストレス因子などのさまざまな原因により、生物の一部、器官、またはシステムに影響を与える病理学的状態を意味します。 RSウイルスが一般的な呼吸器ウイルスとして幅広い年齢層の人々に影響を及ぼしていることを考えると、特に幼児や高齢者など脆弱な人口統計における感染率の急増は、効果的な治療介入の緊急の必要性を浮き彫りにしています。たとえば、2023年にクリーブランドクリニックが発表したデータによると、米国では推定5万7,000人の5歳未満の子供がRSVにより毎年入院を必要としています。したがって、疾病率の上昇は、RSウイルス（RSV）治療薬市場の拡大の原動力となっています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のRSウイルス（RSV）治療薬市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • パリビズマブ
  • リバビリン
  • その他の薬剤
  • 世界のRSウイルス（RSV）治療薬市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 免疫予防
  • 支持療法
  • 抗ウイルス薬
  • 世界のRSウイルス（RSV）治療薬市場、剤形別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 経口
  • 注射
  • その他の剤形
  • 世界のRSウイルス（RSV）治療薬市場、患者タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 小児
  • 大人
  • 世界のRSウイルス（RSV）治療薬市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第7章 地域および国の分析

  • 世界のRSウイルス（RSV）治療薬市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のRSウイルス（RSV）治療薬市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • RSウイルス（RSV）治療薬市場の競合情勢
  • RSウイルス（RSV）治療薬市場の企業プロファイル
    • Johnson &Johnson
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co. Inc.
    • AbbVie Inc.
    • Novartis AG

第31章 その他の大手および革新的な企業

  • Sanofi SA
  • AstraZeneca PLC
  • Abbott Laboratories
  • GlaxoSmithKline plc.
  • Gilead Sciences Inc.
  • Moderna Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Bio-Rad Laboratories Inc.
  • Novavax AB
  • Vir Biotechnology Inc.
  • Lupin Limited
  • Kyorin Pharmaceutical Co. Ltd.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r14295

Respiratory syncytial virus (RSV) therapeutics include various treatments and medications designed to manage and treat infections caused by the respiratory syncytial virus. This virus is known to cause respiratory illness, ranging from mild to severe, with higher risks for infants, young children, older adults, and individuals with weakened immune systems.

The main categories of drugs in respiratory syncytial virus (RSV) therapeutics encompass palivizumab, ribavirin, and others. Palivizumab, a monoclonal antibody developed through DNA recombination, is utilized for respiratory infections in children to prevent complications arising from respiratory syncytial virus infection. Treatments are further classified into immune prophylaxis, supportive care, and antiviral medications, available in various dosage forms such as oral, injectable, and others. These therapeutics are accessible through channels including hospital pharmacies, retail pharmacies, and online pharmacies, catering to patients ranging from pediatrics to adults.

The respiratory syncytial virus (RSV) therapeutics research report is one of a series of new reports from The Business Research Company that provides respiratory syncytial virus (RSV) therapeutics market statistics, including the respiratory syncytial virus (RSV) therapeutics industry's global market size, regional shares, competitors with a respiratory syncytial virus (RSV) therapeutics market share, detailed respiratory syncytial virus (RSV) therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the respiratory syncytial virus (RSV) therapeutics industry. This respiratory syncytial virus (RSV) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The respiratory syncytial virus (rsv) therapeutics market size has grown exponentially in recent years. It will grow from $1.27 billion in 2023 to $1.59 billion in 2024 at a compound annual growth rate (CAGR) of 25.2%. The growth in the historic period for respiratory syncytial virus (RSV) therapeutics can be attributed to factors such as increased disease awareness, advancements in virology, recognition of pediatric vulnerability, occurrences of epidemic outbreaks, and progress in vaccine development.

The respiratory syncytial virus (rsv) therapeutics market size is expected to see exponential growth in the next few years. It will grow to $3.69 billion in 2028 at a compound annual growth rate (CAGR) of 23.4%. The growth in the forecast period for respiratory syncytial virus (RSV) therapeutics can be attributed to factors such as innovation in biologic therapies, the emergence of new antivirals, a focus on the elderly population, maternal immunization strategies, and increased global research collaborations. Major trends in the forecast period include advancements in monoclonal antibodies, the development of nasal vaccines and delivery systems, exploration of combination therapies, innovation in novel drug delivery systems, and the development of home-based treatment options.

The surge in RSV infection prevalence is fueling the expansion of the market for respiratory syncytial virus (RSV) therapeutics. RSV stands as a prevalent respiratory ailment that can cause mild to severe respiratory infections, particularly among newborns, young children, the elderly, and individuals with compromised immune systems. The escalating occurrences of RSV infections are driving the necessity for novel treatments to cater to the increasing demand and alleviate the severity of RSV-associated complications. As evidenced in a September 2022 publication from The Lancet, approximately 11,255 new RSV cases were reported during the 2021 summer, marking a 9.50% increase compared to the 10,280 cases recorded in the winter of 2020-21. Thus, the rise in RSV infection prevalence is a significant driver for the growth of the respiratory syncytial virus (RSV) therapeutics market.

The rising rate of disease is a key factor propelling the growth trajectory of the respiratory syncytial virus (RSV) therapeutics market. A disease signifies a pathological condition affecting a part, organ, or system of an organism due to various causes, including infection, genetic anomalies, or environmental stressors. Given RSV's widespread impact as a common respiratory virus affecting individuals across age groups, the surge in infection rates, particularly among vulnerable demographics such as infants and the elderly, underscores the urgent need for effective therapeutic interventions. For example, according to data released by the Cleveland Clinic in 2023, an estimated 57,000 children under 5 years require hospitalization annually in the U.S. due to RSV. Consequently, the escalating disease rate is a driving force behind the expansion of the respiratory syncytial virus (RSV) therapeutics market.

Developing more effective drugs and vaccines stands as a prominent trend gaining traction within the respiratory syncytial virus (RSV) therapeutics market. Key companies operating in this domain are dedicating their efforts towards creating innovative drugs and vaccines to maintain their market presence. For instance, in May 2023, Pfizer Inc., a renowned pharmaceutical manufacturer in the United States, secured approval from the Food and Drug Administration (FDA), a federal agency responsible for safeguarding public health, for ABRYSVO. This bivalent RSV prefusion F (RSVpreF) vaccine, ABRYSVO (Respiratory Syncytial Virus Vaccine), is administered to prevent lower respiratory tract illnesses caused by RSV in individuals aged 60 and above. ABRYSVO, an unadjuvanted vaccine containing a pair of preF proteins designed to enhance immunity against RSV A and B strains, has demonstrated both safety and efficacy in clinical trials.

Strategic collaborations are emerging as a significant trend gaining momentum within the respiratory syncytial virus (RSV) therapeutics market. Leading companies within this sector are prioritizing the establishment of strategic partnerships to fortify their market positions. For example, in 2023, the Cyrus Poonawalla Group, an India-based biotechnology firm, teamed up with the Serum Institute of India, a prominent biotechnology company specializing in vaccine production, to receive official regulatory clearance for a versatile vaccine. This groundbreaking vaccine aims to combat a wide spectrum of diseases, encompassing polio, tetanus, diphtheria, hepatitis B, mumps, measles, and rubella.

In June 2022, Pfizer Inc., a US-based pharmaceutical manufacturing company, successfully completed the acquisition of ReViral Limited for an undisclosed amount. This strategic move is part of Pfizer's efforts to enhance its pipeline of promising treatment candidates, with a particular focus on sisunatovir. Sisunatovir is an oral antagonist developed to prevent the fusion of the respiratory syncytial virus (RSV) with the host cell. ReViral Limited, headquartered in the UK, is a clinical-stage biotechnology company that specializes in the development of medications targeting RSV.

Major companies operating in the respiratory syncytial virus (rsv) therapeutics market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc., Gilead Sciences Inc., Moderna Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Dr. Reddy's Laboratories Ltd., Bio-Rad Laboratories Inc., Novavax AB, Vir Biotechnology Inc., Lupin Limited, Kyorin Pharmaceutical Co. Ltd., Bavarian Nordic A/S, SciClone Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Hetero Healthcare Ltd, Inovio Pharmaceuticals Inc., Ascletis Pharma Inc., NanoBio Corporation, Vaxart Inc., Ark Biosciences Private Limited, Pulmocide Ltd

North America was the largest region in the respiratory syncytial virus (RSV) therapeutics market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory syncytial virus (rsv) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the respiratory syncytial virus (rsv) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The respiratory syncytial virus (RSV) therapeutics market includes revenues earned by entities by providing services such as home care and respiratory support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The respiratory syncytial virus (RSV) therapeutics market consists of sales of antiviral drugs, monoclonal antibodies, and vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Respiratory Syncytial Virus (RSV) Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on respiratory syncytial virus (rsv) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for respiratory syncytial virus (rsv) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respiratory syncytial virus (rsv) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Drug: Palivizumab; Ribavirin; Other Drugs
  • 2) By Treatment: Immune Prophylaxis; Supportive Care; Antiviral Medications
  • 3) By Dosage Form: Oral; Injectable; Other Dosage Forms
  • 4) By Patient Type: Pediatrics; Adults
  • 5) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • Companies Mentioned: Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Respiratory Syncytial Virus (RSV) Therapeutics Market Characteristics

3. Respiratory Syncytial Virus (RSV) Therapeutics Market Trends And Strategies

4. Respiratory Syncytial Virus (RSV) Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size and Growth

  • 5.1. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Respiratory Syncytial Virus (RSV) Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Respiratory Syncytial Virus (RSV) Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Respiratory Syncytial Virus (RSV) Therapeutics Market Segmentation

  • 6.1. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Palivizumab
  • Ribavirin
  • Other Drugs
  • 6.2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Immune Prophylaxis
  • Supportive Care
  • Antiviral Medications
  • 6.3. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Dosage Form, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injectable
  • Other Dosage Forms
  • 6.4. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Patient Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Pediatrics
  • Adults
  • 6.5. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

7. Respiratory Syncytial Virus (RSV) Therapeutics Market Regional And Country Analysis

  • 7.1. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Respiratory Syncytial Virus (RSV) Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 8.1. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 9.1. China Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 9.2. China Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 10.1. India Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 11.1. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 11.2. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 12.1. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 13.1. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 14.1. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 14.2. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 15.1. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 15.2. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 16.1. UK Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 17.1. Germany Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 18.1. France Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 19.1. Italy Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 20.1. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 21.1. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 21.2. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 22.1. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 23.1. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 23.2. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 24.1. USA Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 24.2. USA Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 25.1. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 25.2. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 26.1. South America Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 26.2. South America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 27.1. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 28.1. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 28.2. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market

  • 29.1. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Overview
  • 29.2. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Respiratory Syncytial Virus (RSV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Landscape
  • 30.2. Respiratory Syncytial Virus (RSV) Therapeutics Market Company Profiles
    • 30.2.1. Johnson & Johnson
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. F. Hoffmann-La Roche Ltd.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Merck & Co. Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. AbbVie Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Respiratory Syncytial Virus (RSV) Therapeutics Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A.
  • 31.2. AstraZeneca PLC
  • 31.3. Abbott Laboratories
  • 31.4. GlaxoSmithKline plc.
  • 31.5. Gilead Sciences Inc.
  • 31.6. Moderna Inc.
  • 31.7. Teva Pharmaceutical Industries Ltd.
  • 31.8. Regeneron Pharmaceuticals Inc.
  • 31.9. Bausch Health Companies Inc.
  • 31.10. Dr. Reddy's Laboratories Ltd.
  • 31.11. Bio-Rad Laboratories Inc.
  • 31.12. Novavax AB
  • 31.13. Vir Biotechnology Inc.
  • 31.14. Lupin Limited
  • 31.15. Kyorin Pharmaceutical Co. Ltd.

32. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Benchmarking

33. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Respiratory Syncytial Virus (RSV) Therapeutics Market

35. Respiratory Syncytial Virus (RSV) Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Respiratory Syncytial Virus (RSV) Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Respiratory Syncytial Virus (RSV) Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Respiratory Syncytial Virus (RSV) Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer